Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05218096 · ClinicalTrials.gov registry record · Phase 2
Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis
A Phase 2 study, sponsored by Alexion Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 70
- Enrollment target
NCT05218096 is a Phase 2 study that was terminated before completion, run by Alexion Pharmaceuticals. The registered enrollment target is 70 participants.
The verdict
NCT05218096, a Phase 2 study, was terminated before completion, sponsored by Alexion Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 70 participants
- Enrollment target
Study Summary
This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
Interventions
- DRUG Placebo
- DRUG ALXN2050
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 70 participants |
| Start Date | 2022-04-27 |
| Est. Completion | 2024-04-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05218096
The ClinicalTrials.gov registry entry for NCT05218096 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 70 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alexion Pharmaceuticals, which has 162 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05218096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05218096 about?
NCT05218096 is a clinical study titled "Study of ALXN2050 in Adult Participants With Generalized Myasthenia Gravis". This study will evaluate the efficacy and safety of ALXN2050 (120 milligrams \[mg\], 180 mg) in participants with generalized myasthenia gravis (gMG). Safety will be monitored throughout the study.
What is the current status of trial NCT05218096?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 70 participants. The study started on 2022-04-27. Estimated completion is 2024-04-03.
What interventions are being tested in trial NCT05218096?
The interventions under investigation include: Placebo (DRUG), ALXN2050 (DRUG).
Who is sponsoring clinical trial NCT05218096?
This trial is sponsored by Alexion Pharmaceuticals, which has 162 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.